Information Provided By: 
Fly News Breaks for March 31, 2015
EGRX
Mar 31, 2015 | 07:32 EDT
Cantor increased its price target on Eagle (EGRX) after the FDA found that Teva's (TEVA) liquid Treanda drug is incompatible with various commonly used polycarbonate-containing injection devices, while the Treanda that Eagle licensed to Teva does not have this problem. The firm thinks this discrepancy will create a number of benefits for Eagle, and it reiterates a Buy rating on the stock.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
